Saudi Arabia an Ambassador to Conquer COVID-19 Pandemic
Received: 22-Apr-2020 / Accepted Date: 12-Jun-2020 / Published Date: 20-Jun-2020 DOI: 10.4172/2161-0711.1000682
Abstract
COVID-19 is a respiratory disease caused by the novel corona virus emerged in China end last quarter of the past year, where so called (2019-nCoV). This virus is highly contagious and spreads easily from human to human or through touching contaminated places. It is responsible for the unexpected outbreak across many countries and regions worldwide. With the major challenges that the governments and healthcare systems are facing during the pandemic. Kingdom of Saudi Arabia (KSA) government moved decisively and proactively taking immediate protective and precautionary measures to ensure the safety of its citizens and residents. Making all efforts at the individual level as well as healthcare and educational levels, to contain the spread of COVID-19. Moreover, Saudi Arabia gathers all powers to battle COVID-19 nationally, regionally and globally. However, with people’s awareness and commitment following the directive measures, KSA will be able to conquer the pandemic and control the crisis.
Keywords: COVID-19; Precautionary measures; Proactive efforts
Introduction
Corona virus disease (COVID) is an infectious illness caused by a novel strain of corona virus. It has emerged in Wuhan city in China late in 2019, and WHO used the interim name 2019-nCoV. Thereafter, it has caused the recent outbreak pandemic respiratory disease, hence called (COVID-19) [1]. At the time, corona virus is attacking more than 200 country around the world [2,3].
Coronaviruses family had been known to cause the common cold MERS; Middle East Respiratory Syndrome and the Severe Acute Respiratory Syndrome; SARS [3]. Nowadays, in 2020, the new virus family member looks like SARS, and is called the SARS corona virus 2 (SARS-CoV-2) that is the COVID-19. Although it has lower severity and mortality than SARS [4], its severity ranged from mild respiratory illness in most healthy people, which does not require special care or treatment. However, it can cause a serious disease in immunecompromised patients like those with an underlying health condition, in addition to old age people [2,5] . The ministry of health (MOH) and the world health organization (WHO) revealed that patient with medical problems such as chronic respiratory disease, chronic asthma, cardiac disease, uncontrolled diabetes, and oncology patients are more vulnerable to develop critical complications. This might require a special kind of healthcare, optimal treatment, and might lead to death in rare cases [2,6].
COVID-19 symptoms, transmission and prevention
The exact mechanism of viral spread is not yet definite. Yet, the Saudi Arabia MOH is working alongside with WHO and other world health experts to discover the pathophysiology, the behaviour of COVID-19 and the reasons behind the infection rate trend. Originally, the corona viruses live in animals, though it can spill over transmitting it into humans and eventually causes human-to-human infection [2]. Likely wise any influenza virus, COVID-19 symptoms include body aches, fatigue, sore throat, running nose, dry cough, fever and shortness of breath [2,3]. It could present as a common harmless flue to a bad cold [7].
The main problem of COVID-19 in comparison to SARS and MERS-CoV lies in being highly contagious, transmissive and spreads very fast between people [3,4]. Primarily, the virus spreads via infected persons droplets, saliva or nasal discharge during sneezing or coughing of an infected patient. COVID-19 is largest among other RNA viruses, it is heavier than remaining in the air for more than seconds, it falls directly into the floor, surfaces and can last for hours [8]. Hence, the best way to slow down the spread of this virus, and preventing the transmission, is through taking all precautions as recommended by the MOH. Keeping a distance of around 2 meters, frequent hand washing, alcohol based hand rubbing, and avoiding touching your face. Moreover, practicing respiratory etiquette, for instance coughing into a flexed elbow or using clean tissue and directly disposing it. Wearing a facial mask if experiencing any symptoms, dealing with or taking care of a positively infected patient, will definitely limit the infection [1,3].
Public health groups, including Centre for Disease Control and Prevention (CDC) as well as WHO are monitoring the pandemic and issued guidelines to confront the crisis and prevent outbreak. Until the moment, there is no specific vaccine or potential anti-viral drug for the COVID-19 treatment. However, many worldwide clinical trials are going on, several of which are really promising. In fact, some people might not show symptoms while some will present with symptoms in 3 to 14 days of infection (the window period). The asymptomatic and those who did not develop symptoms yet can unfortunately spread the infection to all people they contact with. Therefore, till the appropriate treatment is available, the most effective way in preventing the spread would be through social and physical distancing, at the individual level [1,3].
As a result of exponential increase in the positive COVID-19 cases and fatality rate, many countries around the world are applying every possible preparedness activity and preventive measures recommended by public health group [9]. Apparently, Kingdom of Saudi Arabia government is moving decisively and proactively taking immediate measures to ensure safety of citizens and residents. Making all efforts to overcome the unprecedented crisis and contain the spread of COVID-19, while protecting governmental facilities and agencies to ensure the continuity of their tasks.
At the national level
As other countries around the world, Saudi government took a wise decision of travel suspension including domestic and international flights. As well, inter-urban bus transportations, railway and taxi services within the Kingdom were also deferred until further notice. Besides locking down all operations in many governmental zones and commercial centres, in addition to closure of school and any gathering places. Saudi Arabia declared the most important restrictive measures that is to stay at home to mimic the spread, while ensuring the continuous availability of food and medicine supplies. Nonetheless, the two holly mosques in Mecca and Madinah Principality were closed and the Umrah event is banned to avoid the spread through a mass of people. The highest incidence rate cities within Saudi Arabia were subjected to quarantine, while the curfew period was extended in all over the Kingdom [10,11]. As to inspire compelling to these measures, Saudi Arabia government activated numerous online applications to deliver the food and medicine to homes limiting the unnecessary movements.
At the healthcare level
Saudi government provided all appropriate supplies for the healthcare sector to deliver the necessary health services in addition to, resources for infection control, prevention and treatment. Furthermore, the Kingdom of humanity offered to cover all medical expenses to treat all coronavirus patients in the Kingdom. The Saudi armed forces have also joined in competing the COVID-19 crisis by setting up mobile hospitals supplied with advanced equipment and qualified medical teams in various cities. Other military efforts included early detection by triaging and filtering cases prior to their admission to main hospitals [12].
Whereas, all confirmed positive cases undergo quarantine in wellequipped health institutes with full coverage of treatment and care services. The government has shown extreme care to travellers returning to Saudi Arabia, as they are not permitted to enter the kingdom unless they are quarantined for 14 days in high standard hotels with full coverage of residential, healthcare and food services, until declared corona virus free. Saudi Arabia is very considerate about its citizens residing in foreign countries for either for education or business purpose. It took care of them via providing with homing, healthcare and food services in those countries until the government facilitate their return to homeland safely. All Saudi students with scholarships to foreign countries are provided with substantial care services correspondingly as directed by Saudi embassy [10,13].
At an international level
The Kingdom via the Custodian of the Two Holy Mosques has lead international efforts to battle the novel COVID-19 pandemic. Through its presidency of the G20 summit in assembling international preparedness to combat and confront the outbreak, while addressing the coronavirus impact on the global economy. Saudi Arabia showed willingness to learn from China ’ s experience of contesting the pandemic [14]. Moreover, Saudi Arabia from across the humanitarian sector initiate donating money to the deprived countries [15], beside what it offered to the people affected by the curfew within Saudi Arabia itself.
At the educational level
The ministry of education in Saudi Arabia encourages the utilization of information communications technology (ICT) in education to facilitate a distance learning vision. Virtual school and elearning have been activated to all educational levels and in all provinces, offered for free during the suspension period as an alternative method. With Kingdom generousness, free computers were offered to those who are in need. “EduNation” is an advanced digital platform designed to assess learning, providing the appropriate tools for both students and educators, with a high social interaction with each other and with parents. Additionally, this platform is a trusted partner and ideal for higher education and international curricula as well [16].
Conclusion
The government of Saudi Arabia represented by the custodian of the two holy mosques has applied all possible preventive measures to contain the COVID-19 outbreak. Aiming to protect both citizens and residents from such unprecedented pandemic witnessed worldwide. It has provided the indispensable financial needs to support the healthcare provision as well as educational sectors, besides preserving the economic level security to all. Honestly, at this challenging crisis, Saudi Arabia gathers all powers to battle COVID-19 nationally, regionally and globally. However, with people commitment and following the directive precautions and preventive measures, Saudi Arabia will be able to conquer the pandemic and control the situation, God willing.
References
- Mohamoud YA, Mumtaz GR, Riome S, Miller D, Raddad LA (2013) The epidemiology of hepatitis C virus in Egypt: A systematic review and data synthesis. BMC Infect Dis 13: 288.
- Chack E, Talal AH, Sherman KE, Schiff ER, Saab S (2011) Hepatitis C virus infection in USA: An estimate of true prevalence. Liver Int 31: 1090-1101.
- Cacoub P, Poynard T, Ghillani P, Charlotte F, Olivi M, et al. (1999) Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment virus C. Arthritis Rheum 42: 2204-2212.
- Cacoub P, Renou C, Rosenthal E, Cohen P, Loury I, et al. (2000) Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. Medicine 79: 47-56.
- Zignego A, Ferri C, Pileri S, Caini P, Bianchi F, et al. (2007) Extrahepatic manifestations of hepatitis C virus infection: A general overview and guidelines for a clinical approach. Dig Liver Dis 39: 217.
- Terrier B, Cacoub P (2013) Renal involvement in HCV-related vasculitis. Clin Res Hepatol Gastroenterol 37: 334-339.
- Zignego A, Bre´chot C (1999) Extrahepatic manifestations of HCV infection: Facts and controversies. J Hepatol 31: 369-376.
- Maasoumy B, Wedemeyer H (2012) Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol 26: 401-412.
- Uto H, Stuver S, Hayashi K, Kumagai K, Sasaki F, et al. (2009) Increased rate of death related to presence of viremia among hepatitis C virus antibody-positive subjects in a community-based cohort study. Hepatology 50: 393-399.
- Bonkovsky HL, Woolley JM (1999) Reduction in health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology 29: 264-270.
- Svirlith N, Pavic S, Terzic D, Delic D, Simonovic J, et al. (2008) Reduced quality of life in patients with chronic viral liver disease as assessed by the SF-12 questionnaire. J Gastrointest Liver Dis 17: 405-409.
- DiBonaventura MD, Wagner JS, Yuan Y, L'Italien G, Langley P, et al. (2010) Humanistic and economic impacts of hepatitis C infection in the United States. J Med Econ 13: 709-718.
- Hsu PC, Federico CA, Krajden M, Yoshida EM, Bremner KE, et al. (2012) Health utilities and psychometric quality of life in patients with early- and late-stage hepatitis C virus infection. J Gastroenterol Hepatol 27: 149-157.
- Chong CA, Gulamhussein A, Heathcote EJ, Lilly L, Sherman M, et al. (2003) Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol 98: 630-638.
- Bezemer G, van Gool AR, Verjeij-Hart E, Hansen BE, Lurie Y, et al. (2012) Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life: an international, multicenter, randomized, controlled study. BMC Gastroenterol 12: 11.
- Ware JE, Bayliss MS, Mannocchia M, Davis GL (1999) Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group. Hepatology 30: 550-555.
- Carithers RL, Sugano D, Bayliss M (1996) Health assessment for chronic HCV: Results of HQL. Dig Dis Sci 41: 75S-80S.
- Forton DM (2012) Hepatitis C treatment-Clearing the mind. J Hepatol 56: 513-514.
- Senzolo M, Schiff S, D’Aloiso CM, Crivellin C, Cholongitas E, et al. (2011) Neuropsychological alterations in hepatitis C infection: the role of inflammation. World J Gastroenterol 17: 3369-3374.
- Bouffard P, Hayashi P, Acevedo R, Levy N, Zeldis JB (1992) Hepatitis C virus is detected in monocyte/macrophage subpopulation of peripheral blood mononuclear cells of infected patients. J Infect Dis 166: 1276-1282.
- Foster GR, Goldin RD, Thomas HC (1998) Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 27: 209-212.
- Younossi Z, Kallman J, Kincaid J (2007) The effects of HCV infection and management on health-related quality of life. Hepatology 45: 806-816.
- Adinolfi L, Restivo L, Zampino R, Guerrera B, Lonardo A, et al. (2012) Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis. Atherosclerosis 221: 496-502.
- Backus L, Boothroyd D, Phillips B, Belperio P, Halloran J, et al. (2011) A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 9: 509-516.
- Hsu Y, Lin J, Ho H, Kao Y, Huang Y, et al. (2014) Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology 59: 1293-1302.
- Kallman J, O’Neil M, Larive B, Boparai N, Calabrese L, et al. (2007) Fatigue and health-related quality of life (HRQL) in chronic hepatitis C virus infection. Dig Dis Sci 52: 2531-2539.
- Rodger AJ, Jolley D, Thompson SC, Lanigan A, Crofts N (1999) The impact of diagnosis of hepatitis C virus on quality of life. Hepatology 30: 1299-1301.
- Rasenack J, Zeuzem S, Feinman SV, Heathcote EJ, Manns M, et al. (2003) Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: In patients with chronic hepatitis C. Pharmacoeconomic 21: 341-319.
- Hassanein T, Cooksley G, Sulkowski M, Smith C, Marinos G, et al. (2004) The impact of peginterferon alfa- 2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. J Hepatol 40: 675-681.
- Feeney ER, Chung RT (2014) Antiviral treatment of hepatitis C. BMJ 348: g3308.
- Terkawi AS, Tsang S, AlKahtani GJ, Al-Mousa SH, Al Musaed S, et al. (2017) Development and validation of Arabic version of the hospital anxiety and depression scale. Saudi J Anaesth 11: S11-S18.
- Lins L, Carvalho FM (2016) SF-36 total score as a single measure of health-related quality of life: scoping review. SAGE Open Med 4: 205.
- Campolina AG, Bortoluzzo AB, Ferraz MB, Ciconelli RM (2011) Validação da versão brasileira do questionário genérico de qualidade de vida short-form 6 dimensions (SF-6D Brasil). Cienc Saude Coletiva 16: 3103-3110.
- Häuser W, Holtmann G, Grandt D (2004) Determinants of health-related quality of life in patients with chronic liver diseases. Clin Gastroenterol Hepatol 2: 157-163.
- Panzini RG, Mosqueiro BP, Zimpel RR, Bandeira DR, Rocha NS, et al. (2017) Quality-of-life and spirituality. Int Rev Psychiatry 29: 263-282.
- Barker A (1990) The quality of life: The missing measurement in health care. J R Soc Med 83: 539-540.
- Wilson IB, Cleary PD (1995) Linking clinical variables with health-related quality of life. JAMA 273: 59-65.
- Drossman DA (1996) Gastrointestinal illness and the biopsychosocial model. J Clin Gastroenterol 22: 252–254.
- World Health Organization (2016) Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection: Updated version, April 2016, guidelines. Geneva.
- Osoba D (1999) Guidelines for measuring health-related quality of life in clinical trials. New York: Oxford University Press 19-36.
- Gralnek IM, Hays RD, Kilbourne A, Rosen HR, Keeffe EB, et al. (2000) Development and evaluation of the Liver disease quality of life instrument in persons with advanced, chronic liver disease–the LDQOL 1.0. Am J Gastroenterol 95: 3554-3565.
- Mascia C, Vita S, Zuccala P, Marocco R, Tieghi T, et al. (2017) Changes in inflammatory biomarkers in HCV-infected patients undergoing direct acting antiviral-containing regimens with or without interferon. PLoS One 12: e0179400.
- Dolmazashvili E, Abutidze A, Chkhartishvili N, Karchava M, Sharvadze L, et al. (2017) Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA experience. Eur J Gastroenterol Hepatol 29: 1223-1230.
- Tada T, Kumada T, Toyoda H, Mizuno K, Sone Y, et al. (2017) Improvement of liver stiffness in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response. J Gastroenterol Hepatol 32: 1982-1988.
- Siqueira FM, Ferreira VL, Borba HHL, Pontarolo R (2018) Quality of life of Brazilian chronic hepatitis C patients treated with interferon-free therapies. Rev Inst Med Trop Sao Paulo 60: e72.
- Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, et al. (2005) Impact of hepatitis C on health related quality of life: A systematic review and quantitative assessment. Hepatology 41: 790-800.
- Ferreira VL, Leonart LP, Tonin FS, Borba HH, Pontarolo R (2018) Sustained virological response in special populations with chronic hepatitis C using interferon-free treatments: a systematic review and meta-analysis of observational cohort studies. Clin Drug Investig 38: 389-400.
- Ferreira VL, Tonin FS, Assis Jarek NA, Ramires Y, Pontarolo R (2017) Effcacy of interferon-free therapies for chronic hepatitis C: A systematic review of all randomized clinical trials. Clin Drug Investig 37: 635-646.
- Ferreira VL, Borba HH, Wiens A, Pedroso ML, Radunz VF, et al. (2018) Effectiveness and tolerability of directacting antivirals for chronic hepatitis C patients in a Southern state of Brazil. Braz J Infect Dis 22: 186-192.
- Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, et al. (2014) ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 370: 1973-1982.
- Younossi ZM, Stepanova M, Henry L, Gane E, Jacobson IM, et al. (2014) Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C. Clin Gastroenterol Hepatol 12: 1349-1359.
- Gerber L, Estep M, Stepanova M, Escheik C, Weinstein A, et al. (2016) Effects of viral eradication with ledipasvir and sofosbuvir, with or without ribavirin, on measures of fatigue in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol 14: 156-164.
- Younossi ZM, Stepanova M, Pol S, Bronowicki JP, Carrieri MP, et al. (2016) The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: The SIRIUS study. Liver Int 36: 42-48.
- Younossi ZM, Stepanova M, Sulkowski M, Foster GR, Reau N, et al. (2016) Ribavirin-free regimen with sofosbuvir and velpatasvir is associated with high efficacy and improvement of patient-reported outcomes in patients with genotypes 2 and 3 chronic hepatitis C: Results from astral-2 and -3 clinical trials. Clin Infect Dis 63: 1042-1048.
- Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, et al. (2014) ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 370: 1973-1982.
Citation: Ahmed HA (2020) Saudi Arabia an Ambassador to Conquer COVID-19 Pandemic. J Community Med Health Educ 10: 682. DOI: 10.4172/2161-0711.1000682
Copyright: © 2020 Ahmed Ah. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Share This Article
Recommended Journals
Open Access Journals
Article Tools
Article Usage
- Total views: 2144
- [From(publication date): 0-2020 - Aug 16, 2024]
- Breakdown by view type
- HTML page views: 1556
- PDF downloads: 588